In the US, Arixtra (fondaparinux systemic) is a member of the drug class factor Xa inhibitors and is used to treat Deep Vein Thrombosis, Deep Vein Thrombosis Prophylaxis after Abdominal Surgery, Deep Vein Thrombosis Prophylaxis after Hip Replacement Surgery, Deep Vein Thrombosis Prophylaxis after Knee Replacement Surgery, Deep Vein Thrombosis - Prophylaxis and Pulmonary Embolism.
Ingredient matches for Arixtra
Fondaparinux Sodium is reported as an ingredient of Arixtra in the following countries:
- Bosnia & Herzegowina
- Croatia (Hrvatska)
- Czech Republic
- South Africa
- United Kingdom
- United States
Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.